Diabetes Pipeline| 200+ Key Players & 200+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

 Breaking News
  • No posts were found

Diabetes Pipeline| 200+ Key Players & 200+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

November 22
18:26 2022
Diabetes Pipeline| 200+ Key Players & 200+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

DelveInsight’s, “Diabetes Pipeline Insights, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Diabetes Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Diabetes Pipeline clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Diabetes Pipeline Report

  • DelveInsight’s Diabetes Pipeline analysis depicts a robust space with 200+ active players working to develop 200+ pipeline treatment therapies.
  • The leading Diabetes Companies are working such as Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Promising Diabetes Pipeline therapies such as LY2963016, Lantus, OAMs, insulin glargine + exenatide + preexisting metformin, LY2963016, Insulin Lispro, 350mg BID (700mg total daily) IMT-002, ORMD-0801, Cotadutide, and others.
  • This segment of the Diabetes pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Recent Developmental Activities in the Diabetes Pipeline Report

  • In December 2019, University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk announced that they have entered into a five-year research collaboration where they will work together on the development of virtual environments focused on modelling of patients with type 2 diabetes.
  • Enavogliflozin (DWP 16001) is an orally available small molecule and sodium glucose transporter 2 inhibitor. The molecule is in phase-3 clinical trials for type-2 diabetic treatment. Enavogliflozin demonstrates the lowering of blood sugar and safety in diabetic patients in phase 2 clinical trials.
  • Golimumab is a human IgG1 monoclonal antibody, derived from immunizing genetically engineered mice with human TNFα. It inhibits soluble and transmembrane forms of TNF-α by binding to their specific receptors and blocking in consequence their bioactivity. It is currently under Phase II development for the treatment of Type 1 diabetes mellitus.

 

Request a sample and discover the recent breakthroughs happening Diabetes pipeline landscape @ Diabetes Pipeline Report

 

Diabetes Overview

Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or alternatively, when the body cannot effectively use the insulin it produces. The vast majority of Diabetes can be classified as either type 1 or type 2 diabetes. Type 1 diabetes is an autoimmune disease is characterized by a lack of insulin production by the pancreas. Type 2 diabetes occurs when body becomes resistant to insulin, and sugar builds up in the blood. About 90% of people with diabetes around the world have type 2. It is largely the result of excess body weight and physical inactivity. Diabetes can cause a heart attack, stroke, blindness, kidney disease, nerve damage, and other serious health problems.

 

Diabetes Emerging Drugs

  • Enavogliflozin – Daewoong
  • Golimumab – Janssen Biotech

 

Diabetes Pipeline Therapeutic Analysis

There are approx. 200+ key companies which are developing the therapies for Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. phase III include, Daewoong.

 

Learn more about the Diabetes emerging pipeline therapies @ Diabetes Clinical Trials

 

Diabetes Pipeline Report Assessment

  • Diabetes Pipeline Product Profiles
  • Diabetes Pipeline Therapeutic Assessment
  • Diabetes Pipeline Assessment
  • Diabetes Inactive drugs assessment
  • Diabetes Unmet Needs

 

Scope of the Diabetes Pipeline Report

  • Coverage- Global
  • Diabetes Companies- Daewoong Tradipitant, Janssen Biotech, Zealand Pharma, Provention Bio, BioRestorative Therapies, Elevian, Kamada, Adocia, Oramed Pharmaceuticals, ImCyse, Histogen, Novo Nordisk, Enthera, ActoBio Therapeutics, Japan Tobacco, Avotres, and others.
  • Diabetes Pipeline Therapies- LY2963016, Lantus, OAMs, insulin glargine + exenatide + preexisting metformin, LY2963016, Insulin Lispro, 350mg BID (700mg total daily) IMT-002, ORMD-0801, Cotadutide, and others.
  • Diabetes Key Companies
  • Diabetes Key Products
  • Diabetes- Unmet Needs
  • Diabetes- Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetes: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetes – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Diabetes Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Enavogliflozin: Daewoong
  11. Mid Stage Products (Phase II)
  12. Golimumab: Janssen Biotech
  13. Early Stage Products (Phase II/I)
  14. IMCY-0098: ImCyse
  15. Pre-clinical and Discovery Stage Products
  16. ENT-001: Enthera
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Diabetes Key Companies
  20. Diabetes Key Products
  21. Diabetes- Unmet Needs
  22. Diabetes- Market Drivers and Barriers
  23. Diabetes- Future Perspectives and Conclusion
  24. Diabetes Analyst Views
  25. Diabetes Key Companies
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Diabetes drugs?
  • How many Diabetes drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetes and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Diabetes current pipeline therapeutics, reach out to @ Diabetes Treatment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/